First Data For ImmunityBio's Memory Cytokine-Enriched NK Cells In Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity
Portfolio Pulse from Benzinga Newsdesk
ImmunityBio, Inc. (IBRX) has announced new data showing promising anti-tumor activity of its Memory Cytokine-Enriched Natural Killer cells (M-ceNK) in small cell lung cancer and other types of neuroendocrine tumors. The M-ceNK cells use the patient's own NK cells, enriched with ImmunityBio's IL-15 superagonist N-803, to recognize and kill cancer targets. The findings were presented at the annual meeting of the Society for Immunotherapy of Cancer (SITC).
November 07, 2023 | 2:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ImmunityBio's new data showing promising anti-tumor activity of its M-ceNK cells in small cell lung cancer and other neuroendocrine tumors could potentially boost the company's stock in the short term.
The announcement of promising new data on ImmunityBio's M-ceNK cells could potentially lead to increased investor confidence in the company's research and development capabilities, which could in turn lead to a rise in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100